Ally Bridge Group’s Intellia Therapeutics NTLA Stock Holding History

Ally Bridge Group’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-60,000	Closed	-$4.36M	–	24
2022 Q1	$4.36M	Sell	60,000 -5,000	-8%	-$424K	3.23%	14
2021 Q4	$7.69M	Hold	65,000	–	–	2.69%	19
2021 Q3	$8.72M	Sell	65,000 -28,127	-30%	-$4.26M	2.56%	18
2021 Q2	$15.1M	Sell	93,127 -131,873	-59%	-$10.3M	3.75%	14
2021 Q1	$18.1M	Hold	225,000	–	–	3.46%	9
2020 Q4	$12.2M	Buy	+225,000	New	+$8.17M	2.1%	16

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Ally Bridge Group's NTLA Position: Q2 2022 in Review

Ally Bridge Group sold out of Intellia Therapeutics (NTLA) in Q2 2022, closing a stake of 60,000 shares — an estimated $4.36M sold.

Ally Bridge Group first reported a position in NTLA in Q4 2020 and held it in 6 quarters. The position peaked at $18.1M in Q1 2021. 299 funds tracked by Wall St. Rank hold NTLA as of Q2 2022.

Ally Bridge Group reported no remaining Intellia Therapeutics position as of Q2 2022 after selling out during the quarter.
Ally Bridge Group sold 60,000 Intellia Therapeutics shares in Q2 2022, an estimated $4.36M.
Ally Bridge Group first reported a position in Intellia Therapeutics in Q4 2020 and held it in 6 quarters.
Ally Bridge Group's Intellia Therapeutics position peaked at $18.1M in Q1 2021.
299 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2022.

Based on Ally Bridge Group's 13F filing for Q2 2022, filed 15 Aug 2022.